Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolbutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | ALB | P02768 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | FBP1 | P09467 | 7/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolbutamide SCHEMBL15918 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL1536920 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL28046582 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL11356450 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL668223 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL4367531 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL28184306 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL11357518 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL7551276 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL8733982 | 0.96 | ALDH1A1 (0.94) | ALDH1A1LMNACYP2C9TSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| CN-117999257-A | Bicyclic heterocyclic derivatives having virus proliferation inhibitory activity and pharmaceutical compositions containing the same | 盐野义制药株式会社 | 2024-05-07 | — | — | CN | disclosed |
| CN-113501821-B | Fused ring derivatives having MGAT-2 inhibitory activity | 盐野义制药株式会社 | 2024-04-09 | — | — | CN | disclosed |
| CN-112533922-B | Polycyclic pyridone derivatives | 盐野义制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| EP-3653625-B1 | FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117362306-A | Amide derivatives having antiviral activity | 盐野义制药株式会社 | 2024-01-09 | — | — | CN | disclosed |
| CN-117327072-A | Polycyclic carbamoyl pyridone derivatives | 盐野义制药株式会社 | 2024-01-02 | — | — | CN | disclosed |
| EP-4257137-A2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVES FOR THE TREATMENT OF HIV | Shionogi & Co., Ltd (JP) | 2023-10-11 | — | — | EP | disclosed |
| CN-112513042-B | Polycyclic carbamoyl pyridone derivatives | 盐野义制药株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-116528850-A | Amide derivatives having antiviral activity | 盐野义制药株式会社 | 2023-08-01 | — | — | CN | disclosed |
| CN-103140221-A | Novel heterocyclic derivatives and pharmaceutical composition containing same | SHIONOGI & CO | 2013-06-05 | — | — | CN | disclosed |
| EP-2511269-A1 | FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP | Shionogi & Co., Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511268-A1 | OXAZINE DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245155-A1 | FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP | SHIONOGI & CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| US-20120238557-A1 | AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER | SHIONOGI & CO., LTD. (JP) | 2012-09-20 | — | — | US | disclosed |
| EP-2500344-A1 | AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER | Shionogi&Co., Ltd. (JP) | 2012-09-19 | — | — | EP | disclosed |
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120059061-A1 | NOVEL ANTI-INFLAMMATORY COMPOUNDS | THE UNIVERSITY OF TOKYO (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-2415748-A1 | NOVEL ANTI-INFLAMMATORY COMPOUNDS | The University of Tokyo (JP) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | ALDH1A1 3128/4885LMNA 3669/4885CYP2C9 3302/4885 |
| US-20120238557-A1 | AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER | APP, APBA1, SLC1A5 | ALDH1A1 2660/4885LMNA 2574/4885CYP2C9 2591/4885 |
| US-20120059061-A1 | NOVEL ANTI-INFLAMMATORY COMPOUNDS | ALOX15, ALOX15B, ALOX12 | ALDH1A1 1074/4885LMNA 4387/4885CYP2C9 1084/4885 |
| US-20120245155-A1 | FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP | APP, IAPP, BACE1 | ALDH1A1 3901/4885LMNA 873/4885CYP2C9 1417/4885 |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | MGAT2, MGAT1, ACAT2 | ALDH1A1 1270/4885LMNA 4291/4885CYP2C9 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.